anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Melatonin
Trial phase: Phase 3
ATC code: N05CH01
SMILES: COc1ccc2[nH]cc(CCNC(C)=O)c2c1
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 136
Group description: 5 mg Melatonin nightly, beginning within 24 hours of admission

Melatonin
Eligibility criteria:
Inclusion Criteria:

Inpatient admission to a general internal medicine service

Exclusion Criteria:

expected lifespan or length of stay ≤ 48 hours
Non-English speaking
Already taking melatonin or ramelteon at the time of randomization
Presence of delirium at the time of randomization
Unable to take oral medications
Subject or proxy unable to provide informed consent within 18 hours of invitation or 24 hours of admission
ALT or AST (Liver function tests) > 3 times the upper limit of normal
Taking warfarin, nifedipine or fluvoxamine
Allergy to melatonin
Unable to recall 3 words after distraction by naming the days of the week backwards beginning with Sunday
Intervention: Ketamine
Trial phase: Phase 2
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 55
Group description: Low Dose Ketamine (.20 mg/kg)

Ketamine: FDA approved anesthetic medication with rapid acting antidepressant effects.
Eligibility criteria:
Inclusion Criteria:

male or female Veterans or active duty military personnel between the ages of 18 and 70 years
diagnosis of PTSD
history of trialing one or more antidepressant medications with little to no PTSD symptom improvement
ability to provide written informed consent

Exclusion Criteria:

females who are currently pregnant or breastfeeding
current high risk for suicide
history of severe head injury
Intervention: Dalfampridine
Trial phase: Phase 2
ATC code: N07XX07
SMILES: Nc1ccncc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Dalfampridine: Dalfampridine 10 mg extended release 3 hrs before sleep
Eligibility criteria:
Inclusion Criteria:

Healthy control subjects

Exclusion Criteria:

Cardiovascular disease other than well controlled hypertension
History of seizures
Intervention: Oliceridine
Trial phase: Phase 3
ATC code: N02AX07
SMILES: COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 768
Group description: For clinician-administered bolus dosing, TRV130 initial dose is administered and supplemental dosing is available, if clinically indicated. Subsequent doses may be administered every 1 to 3 hours as needed.

For PCA dosing, the TRV130 regimen consists of a loading dose, a demand dose, and a lockout interval.
Eligibility criteria:
Inclusion Criteria include:

Moderate to severe acute pain for which parenteral opioid therapy is warranted
Able to understand and comply with the procedures and study requirements, and to provide written informed consent before any study procedure.

Exclusion Criteria include:

Clinically significant medical, surgical, postsurgical, psychiatric or substance abuse condition or history of such condition that would confound the interpretation of safety, tolerability, or efficacy data in the study.
Hemodynamic instability or respiratory insufficiency.
Advanced cancer in palliative or end-of-life care.
Another current painful condition (other than acute pain for which parenteral opioid therapy is warranted) that would confound the interpretation of safety, tolerability, or efficacy data in the study.
Clinically significant, immune-mediated hypersensitivity reaction to opioids.
Intervention: DEXTROSE
Trial phase: Phase 4
ATC code: B05CX01 | C05BB56 | V04CA02 | V06DC01
SMILES: OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 47
Group description: An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects

Glucose: Sclerotherapy of telangiectasis in one lower limb.
Eligibility criteria:
Inclusion Criteria:

females
with telangiectasis on thigh side
clinical classification of chronic venous disease C1(mild venous disease),
minimum age of 18 year-old and maximum age 65 year-old
agreement with the study
signing the free and informed consent ( IC)
not use anticoagulant drugs .

Exclusion Criteria:

male
varicose disease in any quantity or location with clinical classification of chronic venous disease different of C1(mild venous disease)
restrict mobility
arterial insufficiency
be allergic to any substance that may be related to the study drugs
any cause of dermatitis on application site
don´t be free of comorbidities clinically serious as diabetes mellitus, heart failure, respiratory failure, uncontrolled hypertension with medication, and uncontrolled hypothyroidism
pregnancy
previous deep vein thrombosis (DVT)
family history of DVT
thrombophilia
do not agree with the search terms
Intervention: Polidocanol
Trial phase: Phase 4
ATC code: C05BB02
SMILES: CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 51
Group description: An application session 0.2% Polidocanol + 70% Glucose to treat telangiectasis of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects

Polidocanol with Glucose: Sclerotherapy of telangiectasis in one lower limb.
Eligibility criteria:
Inclusion Criteria:

females
with telangiectasis on thigh side
clinical classification of chronic venous disease C1(mild venous disease),
minimum age of 18 year-old and maximum age 65 year-old
agreement with the study
signing the free and informed consent ( IC)
not use anticoagulant drugs .

Exclusion Criteria:

male
varicose disease in any quantity or location with clinical classification of chronic venous disease different of C1(mild venous disease)
restrict mobility
arterial insufficiency
be allergic to any substance that may be related to the study drugs
any cause of dermatitis on application site
don´t be free of comorbidities clinically serious as diabetes mellitus, heart failure, respiratory failure, uncontrolled hypertension with medication, and uncontrolled hypothyroidism
pregnancy
previous deep vein thrombosis (DVT)
family history of DVT
thrombophilia
do not agree with the search terms
Intervention: Risperidone
Trial phase: Phase 2
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 66
Group description: Two, 300 mg Risperidone Implants

Risperidone Implant
Eligibility criteria:
Inclusion Criteria:

Subject (and/or a subject's authorized legal representative) has provided written informed consent

Patient meets the following criteria:

Outpatient status
PANSS Total Score ≤ 80 at screening and if PANSS score at baseline is ≥ 20% change from screening, the patients cannot participate in the study.

A score of ≤ 3 on the following PANSS items:

Conceptual disorganization
Suspiciousness
Hallucinatory behavior
Unusual thought content
Subject is male or female between 18 to 60 years of age
Subject has a diagnosis of schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria

Exclusion Criteria:

Hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the Investigator
Subject has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide
Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening.
Have impaired hepatic (ALT/AST >1.5 times higher than the upper limit of normal) or renal function (eGFR<50 mL/min)
Previously defined hypersensitivity to Risperidone
History of neuromalignant syndrome (NMS)
Electroconvulsive therapy within 6 months of admission
Requires current use of agents that are strong inhibitors and inducers of cytochrome P450 2D6
Intervention: Risperidone
Trial phase: Phase 2
ATC code: N05AX08
SMILES: Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 66
Group description: Three, 300 mg Risperidone Implants

Risperidone Implant
Eligibility criteria:
Inclusion Criteria:

Subject (and/or a subject's authorized legal representative) has provided written informed consent

Patient meets the following criteria:

Outpatient status
PANSS Total Score ≤ 80 at screening and if PANSS score at baseline is ≥ 20% change from screening, the patients cannot participate in the study.

A score of ≤ 3 on the following PANSS items:

Conceptual disorganization
Suspiciousness
Hallucinatory behavior
Unusual thought content
Subject is male or female between 18 to 60 years of age
Subject has a diagnosis of schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria

Exclusion Criteria:

Hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the Investigator
Subject has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide
Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening.
Have impaired hepatic (ALT/AST >1.5 times higher than the upper limit of normal) or renal function (eGFR<50 mL/min)
Previously defined hypersensitivity to Risperidone
History of neuromalignant syndrome (NMS)
Electroconvulsive therapy within 6 months of admission
Requires current use of agents that are strong inhibitors and inducers of cytochrome P450 2D6
Intervention: Epicatechin
Trial phase: Phase 2
SMILES: Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Total daily dose 75mg (+)-Epicatechin; 25mg cap three times per day by mouth for 24 weeks

(+)-Epicatechin: 25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
Eligibility criteria:
Inclusion Criteria:

Confirmed diagnosis of Friedreich's Ataxia (FA) by Frataxin genetic testing and/or Frataxin enzyme analysis
Between age 10 and 50 years of age, inclusive
Body weight of 25 kilograms or higher
Minimum of one affected organ (cardiac or neurological) system, as evidenced by clinical signs/symptoms
Disease duration ≤7 years, based on onset date of FA symptoms
Has no known contraindication to gadolinium contrast such as severe allergy or Glomerular Filtration Rate <30 ml/min/m^2.
Has no known contraindication to non-contrast Magnetic Resonance Imaging (MRI) evaluation such as pacemaker or magnetically active metal fragments.

Women of childbearing age must:

Have a negative pregnancy human chorionic gonadotropin test prior to receiving study drug.
Agree to use contraception for the duration of the study drug dosing, plus 1 month after completion of the study.

Exclusion Criteria:

Advanced cardiac failure, New York Heart Association (NYHA) Classification Scale-Class IV (advanced stage heart failure)
Clinically significant comorbidities that may also lead to cardiomyopathy, for example long standing hypertension, familial cardiomyopathy.
Clinically significant comorbidities that would, in the opinion of the investigators, compromise the interpretation of test results.
Pregnant, breast-feeding or planning to become pregnant during study timeframe.
Patients with contraindications to regadenoson, i. e. second- or third-degree atrioventricular (AV) block or sinus node dysfunction. Has received an investigational drug within thirty (30) days of baseline visit.
Thrombocytopenia (<125 x 10^9/Liter) or prolonged Prothrombin Time/Partial Thromboplastin Time (PT/PTT) at baseline.
Clinically significant hypotension (systolic blood pressure <90) due to heart failure or other conditions.
Intervention: OC-459
Trial phase: Phase 2
SMILES: Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 22
Group description: OC459 50mg once daily for 5 weeks

Rhinovirus: Inoculation with rhinovirus serotype 16
Eligibility criteria:
Inclusion Criteria:

Age 18--55 years
Male or female
Clinical diagnosis of asthma for at least 6 months prior to screening
An Asthma Control Questionnaire (ACQ) Score >0.75
Positive histamine challenge test (PC20 <8 µg/ml, or <12 µg/ml and bronchodilator response ≥ 12%)
Worsening asthma symptoms with infection since last change in asthma therapy
Positive skin prick test to common aeroallergens (e.g. animal epithelia, dust mite)
Treatment comprising inhaled corticosteroids (ICS) or combination inhaler (Long -Acting Beta Agonist with ICS), with a daily ICS dose of at least 100mcg fluticasone or equivalent.
Participant is willing for their GP to be informed of their participation.
English speaker

Exclusion Criteria:

Presence of clinically significant diseases other than asthma, which, in the opinion of the investigator, may either put the patient at risk because of participation in the trial, or diseases which may influence the results of the study or the patient's ability to take part in it
Smoking history over past 12 months
Seasonal allergic rhinitis symptoms at screening
Asthma exacerbation or viral illness within the previous 6 weeks
Current or concomitant use of oral steroids, anti--leukotrienes or monoclonal antibodies
Pregnant or breast-feeding women (patients should not be enrolled if they plan to become pregnant during the time of study participation)
Contact with infants <6 months or immunocompromised persons, elderly and infirm at home or at work
Subjects who have known evidence of lack of adherence to medications and/or ability to follow physician's recommendations
Intervention: Bupivacaine
Trial phase: Not Applicable
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 41
Group description: Women undergoing endometrial ablation that meet the eligibility criterial will receive a standardized paracervical injection of Bupivacaine 20 mL 0.25% at the completion of the procedure.

Bupivacaine: Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
Eligibility criteria:
Inclusion Criteria:

Premenopausal women
English as primary language
undergoing outpatient endometrial ablation at the Christiana Hospital Surgical Center
Indication of menorrhagia
Inication of abnormal uterine bleeding
Indication of thickened endometrium.

Exclusion Criteria:

Known malignancy
weight less than 50 Kg
amide allergy
history of chronic pain
cardiac arrhythmia
dilaudid/codeine allergy
history of opioid use
inability to take opioids by mouth
uterine anomaly
previous endometrial ablation
primary language other than English.
Intervention: Ketamine
Trial phase: Phase 1
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 5
Group description: Trial Interventions: participants will receive four two-weekly infusions of ketamine at 0.05mg/kg. All infusions will be administered by a consultant anaesthetist.

Ketamine: A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
Eligibility criteria:
Inclusion Criteria:

≥18 years old
Hamilton Rating Scale for Depression, 24-item (HRSD-24) score of ≥21
Voluntary admission for treatment of acute depressive episode
Meet DSM-IV criteria for recurrent depressive disorder (RDD): ≥2 previous depressive episodes with at least 2-months(consecutive) subthreshold or no symptoms in between PLUS(to enrich the sample for those at high risk for relapse) must also have experienced ≥3 major depressive episodes(including index episode) within the previous 2 years

For the randomised pilot trial, RDD patients must have:

received antidepressant treatment for the acute depressive episode(pharmacological, psychotherapeutic or multidisciplinary)
≥60% decrease from baseline HRSD-24 score and score ≤16
Standardised Mini-Mental State Examination (sMMSE) score of ≥24
able to provide informed consent

Exclusion Criteria:

Current involuntary admission
Medical condition rendering unfit for ketamine/midazolam
Active suicidal intention
Dementia
History of Axis 1 diagnosis other than RDD
Electroconvulsive therapy (ECT) for treatment of current depressive episode
Alcohol/substance abuse in previous six months
Pregnancy or inability to confirm use of adequate contraception during the trial
Intervention: Midazolam
Trial phase: Phase 1
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Trial Interventions: participants will receive four two-weekly infusions of midazolam at 0.045mg/kg. All infusions will be administered by a consultant anaesthetist.

Midazolam: A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
Eligibility criteria:
Inclusion Criteria:

≥18 years old
Hamilton Rating Scale for Depression, 24-item (HRSD-24) score of ≥21
Voluntary admission for treatment of acute depressive episode
Meet DSM-IV criteria for recurrent depressive disorder (RDD): ≥2 previous depressive episodes with at least 2-months(consecutive) subthreshold or no symptoms in between PLUS(to enrich the sample for those at high risk for relapse) must also have experienced ≥3 major depressive episodes(including index episode) within the previous 2 years

For the randomised pilot trial, RDD patients must have:

received antidepressant treatment for the acute depressive episode(pharmacological, psychotherapeutic or multidisciplinary)
≥60% decrease from baseline HRSD-24 score and score ≤16
Standardised Mini-Mental State Examination (sMMSE) score of ≥24
able to provide informed consent

Exclusion Criteria:

Current involuntary admission
Medical condition rendering unfit for ketamine/midazolam
Active suicidal intention
Dementia
History of Axis 1 diagnosis other than RDD
Electroconvulsive therapy (ECT) for treatment of current depressive episode
Alcohol/substance abuse in previous six months
Pregnancy or inability to confirm use of adequate contraception during the trial
Intervention: Ferric citrate
Trial phase: Phase 4
ATC code: V03AE08
SMILES: O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Fe+3]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: Ferric citrate at a starting dose of 2 tablets with each meal will be given to all participants.

Ferric Citrate: Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and < 50% and ferritin ≥ 200 and < 500 ng/ml after a 2 week wash out period.
Eligibility criteria:
Inclusion Criteria:

Hemodialysis treatment for ≥ 6 months
Phosphate binder treatment for ≥ to 1 month
Maintenance iron therapy with no more than 125mg IV iron weekly≥ to 1 month
Serum phosphorus levels between 2.5 and 8 at screening
Serum phosphorus ≥ to 6.0 mg/dL after a 2 week washout period.
Serum ferritin ≥ 200 and < 600ng/ml after a 2 week washout period
Serum calcium levels within normal range
Predicted survival greater than 6 months

Exclusion Criteria:

Intact PTH< 70 pg/ml or > 1,000 pg/ml
Oral iron use
Vitamin C supplement use
Parathyroidectomy
Active malignancy
Hemodialysis via an intravenous catheter or arteriovenous (AV) graft
Received > 250mg of IV iron over the two weeks prior to screening
Whole blood transfusion within 3 months prior to screening
Active bleeding other than from the dialysis access
Hospitalization within one month prior to screening
current infection
Ongoing or uncontrolled inflammatory disorder
Liver cirrhosis
Likelihood of imminent renal transplantation
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: -TAP block of 266 mg/30 cc liposomal bupivacaine
Eligibility criteria:
Inclusion Criteria:

Scheduled for abdominal-based autologous breast reconstruction (DIEP, MS-TRAM, or TRAM).
At least 18 years of age.
Female.
Able to understand and willing to sign a written informed consent document.

Exclusion Criteria:

Cognitive impairment.
History of abdominal surgery precluding free flap donor site.
Allergy or intolerance to bupivacaine or "amide" anesthetics.
Significant preoperative chronic pain (requiring daily narcotics) or neuropathic pain (requiring daily use of pregabalin or gabapentin) within the previous 3 months.
Pregnant or breastfeeding.
Intervention: Nitric Oxide
Trial phase: Phase 3
ATC code: R07AX01
SMILES: [N]=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 140
Group description: Sufentanil sublingual tablet (SST) 30 mcg

Sufentanil sublingual tablet (SST) 30 mcg: sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
Eligibility criteria:
Inclusion Criteria:

Male or female patients who are 40 years of age or older.
Patients who have undergone a surgical procedure with general anesthesia or spinal anesthesia that does not include intrathecal opioids during the operation.
Patients classified as American Society of Anesthesiologists (ASA) class IIII (Appendix I).

Exclusion Criteria:

Patients who have taken an opioid for more than 30 consecutive days, at a daily dose of more than 15 mg of morphine (or equivalent), within the past 3 months prior to surgery (e.g. more than 3 doses per day of Vicodin®, Norco®, Lortab® with 5 mg hydrocodone per tablet).
Patients with a positive drug of abuse screen unless the positive test result is consistent with a prescribed medication.
Patients with a history of opioid dependence within 2 years before the start of the study, defined as meeting the DSM-IV-TR™ Criteria for Substance Dependence specified in Appendix II.
Patients who have used any illicit drugs of abuse within five years before the start of the study.
Patients who have abused any prescription medication or alcohol within one year before the start of the study.
Patients with an allergy or hypersensitivity to opioids.
Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug.
Patients with current sleep apnea that has been documented by a sleep laboratory study or are on home continuous positive airway pressure (CPAP).